ATE320264T1 - Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung - Google Patents
Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellungInfo
- Publication number
- ATE320264T1 ATE320264T1 AT97953216T AT97953216T ATE320264T1 AT E320264 T1 ATE320264 T1 AT E320264T1 AT 97953216 T AT97953216 T AT 97953216T AT 97953216 T AT97953216 T AT 97953216T AT E320264 T1 ATE320264 T1 AT E320264T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccine
- overexpressing
- production
- antigen
- organism
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 244000000010 microbial pathogen Species 0.000 abstract 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1997/023032 WO1999029340A1 (en) | 1997-12-05 | 1997-12-05 | An over-expressing homologous antigen vaccine and a method of making the same |
| CNB971825173A CN1321693C (zh) | 1997-12-05 | 1997-12-05 | 一种过量表达的同源抗原疫苗及其制备方法 |
| OA1200000163A OA11421A (en) | 1997-12-05 | 2000-06-05 | An over-expressing homologous antigen vaccine and a method of making the same. |
| US09/692,623 US6811787B1 (en) | 1997-12-05 | 2000-10-20 | Over-expressing homologous antigen vaccine and a method of making the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE320264T1 true ATE320264T1 (de) | 2006-04-15 |
Family
ID=39591168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97953216T ATE320264T1 (de) | 1997-12-05 | 1997-12-05 | Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6149920A (de) |
| EP (1) | EP1035863B1 (de) |
| CN (1) | CN1321693C (de) |
| AT (1) | ATE320264T1 (de) |
| AU (1) | AU759776C (de) |
| BR (1) | BR9714904B1 (de) |
| CA (1) | CA2317806A1 (de) |
| ES (1) | ES2259449T3 (de) |
| NZ (1) | NZ504993A (de) |
| OA (1) | OA11421A (de) |
| PT (1) | PT1035863E (de) |
| WO (1) | WO1999029340A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE320264T1 (de) | 1997-12-05 | 2006-04-15 | Virginia Tech Intell Prop | Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung |
| CN1558773A (zh) * | 2001-04-06 | 2004-12-29 | 巴斯德研究院 | 由与破伤风类毒素结合的霍乱弧菌o139的脂多糖的多糖部分组成的缀合疫苗 |
| WO2004054508A2 (en) * | 2002-12-12 | 2004-07-01 | Walter Reed Army Institute Of Research Department Of The Army | Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments |
| US7364745B2 (en) * | 2004-02-06 | 2008-04-29 | Virginia Tech Intellectual Properties, Inc. | Development of a live, attenuated, recombinant vaccine for Brucellosis |
| WO2005084706A1 (en) * | 2004-03-03 | 2005-09-15 | Walter Reed Army Institute Of Research | Mutant strains of brucella melitensis and immunogenic compositions |
| WO2007050099A2 (en) * | 2004-12-01 | 2007-05-03 | Aeras Global Tb Vaccine Foundation | Recombinant bcg strains with attenuated immunosuppresive properties |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888170A (en) * | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
| US5468485A (en) * | 1987-06-04 | 1995-11-21 | Washington University | Avirulent microbes and uses therefor |
| US6043057A (en) | 1988-09-16 | 2000-03-28 | Vitec Aktiebolag | Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides |
| ATE359370T1 (de) | 1993-02-22 | 2007-05-15 | Gen Hospital Corp | Heterologe antigene in stämmen zur impfung mit lebendzellen |
| DE69434807T2 (de) * | 1993-02-26 | 2007-03-29 | Novozymes A/S | Methode und system zur erhöhten produktion von kommerziell wichtigen exoproteinen in gram-positiven bakterien |
| CA2164298A1 (en) | 1993-06-04 | 1994-12-22 | Richard A. Young | Stress proteins and uses therefor |
| US6036953A (en) | 1996-11-29 | 2000-03-14 | The General Hospital Corporation | Heterologous antigens in live cell V. cholerae strains |
| WO1998046260A1 (en) * | 1997-04-15 | 1998-10-22 | Baylor College Of Medicine | Pasteurella haemolytica vaccine |
| ATE320264T1 (de) * | 1997-12-05 | 2006-04-15 | Virginia Tech Intell Prop | Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung |
-
1997
- 1997-12-05 AT AT97953216T patent/ATE320264T1/de not_active IP Right Cessation
- 1997-12-05 US US09/091,521 patent/US6149920A/en not_active Expired - Lifetime
- 1997-12-05 ES ES97953216T patent/ES2259449T3/es not_active Expired - Lifetime
- 1997-12-05 CN CNB971825173A patent/CN1321693C/zh not_active Expired - Lifetime
- 1997-12-05 WO PCT/US1997/023032 patent/WO1999029340A1/en not_active Ceased
- 1997-12-05 PT PT97953216T patent/PT1035863E/pt unknown
- 1997-12-05 CA CA002317806A patent/CA2317806A1/en not_active Abandoned
- 1997-12-05 EP EP97953216A patent/EP1035863B1/de not_active Expired - Lifetime
- 1997-12-05 NZ NZ504993A patent/NZ504993A/xx unknown
- 1997-12-05 BR BRPI9714904-7A patent/BR9714904B1/pt not_active IP Right Cessation
- 1997-12-05 AU AU57013/98A patent/AU759776C/en not_active Ceased
-
2000
- 2000-06-05 OA OA1200000163A patent/OA11421A/en unknown
- 2000-10-20 US US09/692,623 patent/US6811787B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999029340A1 (en) | 1999-06-17 |
| EP1035863A4 (de) | 2003-04-16 |
| CN1321693C (zh) | 2007-06-20 |
| CA2317806A1 (en) | 1999-06-17 |
| OA11421A (en) | 2004-04-21 |
| US6149920A (en) | 2000-11-21 |
| CN1290173A (zh) | 2001-04-04 |
| PT1035863E (pt) | 2006-07-31 |
| BR9714904B1 (pt) | 2010-07-13 |
| EP1035863B1 (de) | 2006-03-15 |
| EP1035863A1 (de) | 2000-09-20 |
| US6811787B1 (en) | 2004-11-02 |
| AU759776B2 (en) | 2003-05-01 |
| NZ504993A (en) | 2002-11-26 |
| AU5701398A (en) | 1999-06-28 |
| AU759776C (en) | 2004-05-20 |
| ES2259449T3 (es) | 2006-10-01 |
| BR9714904A (pt) | 2001-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE425987T1 (de) | Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung | |
| DE60016461D1 (de) | Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen | |
| DE59502704D1 (de) | Aerogelhaltige zusammensetzung, verfahren zur ihrer herstellung sowie ihre verwendung | |
| ATE107608T1 (de) | Kieselsäuresole, verfahren zur herstellung von kieselsäuresolen sowie verwendung der sole. | |
| GR3034349T3 (en) | Neutralizing monoclonal antibodies to respiratory syncytial virus | |
| NO953601L (no) | Nukleinsyre som koder for en tumorreksjonsantigenforlöper | |
| FI960268A0 (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä | |
| ATE166230T1 (de) | Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock | |
| WO1998014596A3 (en) | Disease associated protein tyrosine phosphatases | |
| DE10193003D2 (de) | Verfahren zur Herstellung bioaktiver Implantatoberflächen | |
| MX2023002948A (es) | Métodos y composiciones para modular la inmunidad mediada por cadena beta. | |
| ATE320264T1 (de) | Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung | |
| PH12020500662A1 (en) | Anti-pfrh5 antibodies and antigen-binding fragments thereof | |
| ATE148708T1 (de) | Verfahren zur reinigung von waessrigen extrakten, die allergenische proteine enthalten, so erhaltene extrakte und ihre verwendung | |
| ATE204905T1 (de) | Verfahren zur herstellung von äthylalkohol | |
| ATE270275T1 (de) | Verfahren zur herstellung von 2-aryl-3-aryl-5- halogen-pyridinen, verwendbar als cox-2 inhibitoren | |
| ATE187440T1 (de) | Verfahren zur herstellung von substituierten 3- aminobenzonitrilen | |
| ATE316135T1 (de) | Monoklonale antikörper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung sowie ihre verwendung | |
| ATE191457T1 (de) | Verfahren zur herstellung von einem bicyclohexanderivat | |
| WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| ATE131488T1 (de) | Neues verfahren zur herstellung von hydrocortison sowie zwischenprodukten dafür | |
| DK0698102T3 (da) | Cholesteroloxidase fra Brevibacterium sterolicum | |
| IT1275909B1 (it) | Frammento di dna codificante d-amminoacido ossidasi | |
| ATE43610T1 (de) | Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung. | |
| DE50203388D1 (de) | Verbessertes verfahren zur herstellung von bisphosphiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |